<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00203502</url>
  </required_header>
  <id_info>
    <org_study_id>UARK 2004-59</org_study_id>
    <nct_id>NCT00203502</nct_id>
  </id_info>
  <brief_title>Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer</brief_title>
  <official_title>Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorubicin in Operable/Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to find out what effects taking the drug bevacizumab
      together with two chemotherapeutic agents, docetaxel and cyclophosphamide followed by
      doxorubicin alone before surgery will on breast cancer. Bevacizumab will be given for twelve
      weeks in combination with chemotherapy then it ill be held during the administration of
      doxorubicin. Twenty-eight to fifty-six days after undergoing surgery, all patients will
      receive nine three-weekly infusions of bevacizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to being enrolled in this study, they will undergo an evaluation to determine
      eligibility. The study doctor will obtain a complete medical history, complete a physical
      examination including blood pressure and heart rate. The doctor will also obtain a baseline
      ECG as well as blood tests (approximately two tablespoons of blood). In order to decrease the
      effects of food, exercise and the sleep/wake cycle variability, all blood samples must be
      taken between 8AM - 10AM and patients will need to fast (no food or drink) for 10 hours prior
      to the blood test. Patients will also need to strain from working out prior to the blood
      test. The study will ask for a list of current medications. Patients will not be eligible if
      they have a history of or now require long-term anticoagulant (blood thinner) therapy (i.e.
      Coumadin or anything patients may be taking to prevent blood clots) have an allergy to
      bevacizumab or any other drugs used in the study.

      Many of the following evaluations are commonly done to determine diagnosis and/or stage of
      breast cancer and may have already had some of all of them done. If the following procedures
      were not done within three weeks, they will need to be done again prior to receiving any
      study therapy.

        -  Diagnosis of breast cancer by fine needle aspiration or core needle biopsy will be
           required for entry in this study.

        -  Clip Placement - a clip will be placed in the tumor during the core biopsies as a marker
           to assist surgeons at the time of surgery.

        -  Tumor Clip Placements - a caliper is similar to a ruler and is used to measure the tumor
           from the outside of the body instead of always having to use an ultrasound or MRI.

        -  Tumor Ultrasound - this is a non-invasive exam that uses sound waves to produce a
           picture of your tumor.

      All study participants will be treated with bevacizumab 15 mg/kg plus docetaxel 75 mg/m2 and
      cyclophosphamide 500 mg/m2 every three weeks for a total of four treatments. Three weeks
      after the completion of this part of the treatment patients will start receiving doxorubicin
      60 mg/m2 every three weeks for a total of four treatments. All these drugs will be given as
      intravenous infusion on the first day of each three-week period.

      Patients will come in for every three week visits and have a physical exam including blood
      pressure and heart rate. Medications lists will be taken and any side effects that may have
      been experienced. Tumor caliper measurements will be done and blood will be drawn at each of
      these visits.

      A mammogram and MUGA scan will be done again just prior to surgery. Patients will undergo
      tumor surgery approximately six months after treatment. Patients will need to visit the study
      physician one month after surgery for another physical examination including blood pressure
      and heart rate, an assessment of any side effects and a list of current medications.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Pathological Complete Response.</measure>
    <time_frame>Participants were assessed during surgery, an average of one hour</time_frame>
    <description>Pathological complete response was defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the resected breast.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Complete Response in Breast and the Axillary Lymph Nodes After the Completion of Chemotherapy and Bevacizumab.</measure>
    <time_frame>At completion of chemotherapy treatment, an average of one hour</time_frame>
    <description>Clinical complete response was defined using RECIST response categories as the clinical response to chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Grade 3 or 4 Adverse Events</measure>
    <time_frame>After each chemotherapy infusion, approximately one hour</time_frame>
    <description>Percent of participants who had at least one grade 3 or 4 adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Measure the Change in Left Ventricular Ejection Fraction (LVEF) From Baseline</measure>
    <time_frame>Immediately before treatment and 1 year after start of treatment</time_frame>
    <description>Absolute change in LVEF, where LVEF values are measured in percentage units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pathologic Complete Response (pCR) Among Those With Triple Negative Breast Cancer</measure>
    <time_frame>at surgery, one day</time_frame>
    <description>pCR rate for triple negative patients--percent</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention: Dtx Cyclophosphamide Bev</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 75m/m2 Cyclophosphamide 500 mg/m2 Bevacizumab 15 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV 15mg/kg 21 days</description>
    <arm_group_label>Intervention: Dtx Cyclophosphamide Bev</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>500mg per meter squared, IV every 21 days</description>
    <arm_group_label>Intervention: Dtx Cyclophosphamide Bev</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>60 mg per meter squared, IV every 21 days</description>
    <arm_group_label>Intervention: Dtx Cyclophosphamide Bev</arm_group_label>
    <other_name>Taxotere</other_name>
    <other_name>Adriamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis of breast cancer established by biopsy.

          -  Normal kidney function

          -  Normal LVEF evaluated by MUGA Scan

          -  &gt;18 years of age

          -  Good performance status defined by ECOG scale of 0 or 1

          -  Consent

          -  Women of childbearing potential must have a negative pregnancy test.

          -  Use of effective means of contraception in subjects of child-bearing potential while
             on treatment and for at least 3 months thereafter.

          -  Peripheral Neuropathy: must be &lt; grade 1

          -  Hematologic (minimal values)

          -  Absolute neutrophil count &gt;1,500/mm3

          -  Hemoglobin &gt;8.0 g/dl

          -  Platelet count &gt;100,000/mm3

          -  Hepatic

          -  Total bilirubin &lt;ULN

          -  AST, ALT, Alkaline Phosphatase must be within range

        Exclusion Criteria:

          -  Patients with locally advanced breast cancer with skin ulcerations

          -  Stage IV breast cancer

          -  Inflammatory breast cancer

          -  Allergy to any component of the treatment regimen

          -  Women who are breast feeding

          -  Pregnancy or refusal to use effective contraception

          -  Inability to comply with study and/or follow-up procedures.

          -  Current, recent, or planned participation in a experimental drug study

          -  Blood pressure of &gt;150/100 mmHg. Essential hypertension well controlled with anti
             hypertensives is not an exclusion criterion.

          -  unstable angina

          -  New York Heart Association Grade II or greater congestive heart failure

          -  history of myocardial infarction within 6 months

          -  history of stroke within 6 months

          -  Clinical significant peripheral vascular disease

          -  Evidence of bleeding diathesis or coagulopathy

          -  Presence of central nervous system or brain metastasis

          -  major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to day 0

          -  Minor surgical procedure such as fine needle aspirations or core biopsy within 7 days
             prior to day 0

          -  Pregnant or lactating

          -  Urine protein: creatinine ratio &gt;1.0 at screening

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to Day 0

          -  Serious, non-healing wound, ulcer, or bone fracture
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issam Makhoul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>October 21, 2015</results_first_submitted>
  <results_first_submitted_qc>November 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2016</results_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Operable and Locally advanced Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study recruited patients from September 9, 2005 through January 17, 2008. Patients were recruited from hematology/oncology clinic at the Winthrop P. Rockefeller Cancer Institute of the University of Arkansas for Medical Sciences.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin</title>
          <description>Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2
+ Avastin 15 mg/kg
Q 3 weeks X 4 cycles
Bevacizumab/Avastin: IV 15mg/kg 21 days
Cyclophosphamide: 500mg per meter squared, IV every 21 days
Doxorubicin: 60 mg per meter squared, IV every 21 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin</title>
          <description>Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2
+ Avastin 15 mg/kg
Q 3 weeks X 4 cycles
Bevacizumab/Avastin: IV 15mg/kg 21 days
Cyclophosphamide: 500mg per meter squared, IV every 21 days
Doxorubicin: 60 mg per meter squared, IV every 21 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="26" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Pathological Complete Response.</title>
        <description>Pathological complete response was defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the resected breast.</description>
        <time_frame>Participants were assessed during surgery, an average of one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin</title>
            <description>Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2
+ Avastin 15 mg/kg
Q 3 weeks X 4 cycles
Bevacizumab/Avastin: IV 15mg/kg 21 days
Cyclophosphamide: 500mg per meter squared, IV every 21 days
Doxorubicin: 60 mg per meter squared, IV every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pathological Complete Response.</title>
          <description>Pathological complete response was defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the resected breast.</description>
          <units>percentage of evaluable patients</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="27.7" upper_limit="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Complete Response in Breast and the Axillary Lymph Nodes After the Completion of Chemotherapy and Bevacizumab.</title>
        <description>Clinical complete response was defined using RECIST response categories as the clinical response to chemotherapy</description>
        <time_frame>At completion of chemotherapy treatment, an average of one hour</time_frame>
        <population>All participants evaluated surgically</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin</title>
            <description>Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2
+ Avastin 15 mg/kg
Q 3 weeks X 4 cycles
Bevacizumab/Avastin: IV 15mg/kg 21 days
Cyclophosphamide: 500mg per meter squared, IV every 21 days
Doxorubicin: 60 mg per meter squared, IV every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Complete Response in Breast and the Axillary Lymph Nodes After the Completion of Chemotherapy and Bevacizumab.</title>
          <description>Clinical complete response was defined using RECIST response categories as the clinical response to chemotherapy</description>
          <population>All participants evaluated surgically</population>
          <units>percentage of pts w/ cCR</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="39" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Grade 3 or 4 Adverse Events</title>
        <description>Percent of participants who had at least one grade 3 or 4 adverse event</description>
        <time_frame>After each chemotherapy infusion, approximately one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin</title>
            <description>Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2
+ Avastin 15 mg/kg
Q 3 weeks X 4 cycles
Bevacizumab/Avastin: IV 15mg/kg 21 days
Cyclophosphamide: 500mg per meter squared, IV every 21 days
Doxorubicin: 60 mg per meter squared, IV every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 3 or 4 Adverse Events</title>
          <description>Percent of participants who had at least one grade 3 or 4 adverse event</description>
          <units>percentage of pts w/ grade 3/4 AE</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="69" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Measure the Change in Left Ventricular Ejection Fraction (LVEF) From Baseline</title>
        <description>Absolute change in LVEF, where LVEF values are measured in percentage units</description>
        <time_frame>Immediately before treatment and 1 year after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin</title>
            <description>Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2
+ Avastin 15 mg/kg
Q 3 weeks X 4 cycles
Bevacizumab/Avastin: IV 15mg/kg 21 days
Cyclophosphamide: 500mg per meter squared, IV every 21 days
Doxorubicin: 60 mg per meter squared, IV every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>To Measure the Change in Left Ventricular Ejection Fraction (LVEF) From Baseline</title>
          <description>Absolute change in LVEF, where LVEF values are measured in percentage units</description>
          <units>Percentage of LVEF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pathologic Complete Response (pCR) Among Those With Triple Negative Breast Cancer</title>
        <description>pCR rate for triple negative patients--percent</description>
        <time_frame>at surgery, one day</time_frame>
        <population>Patients with triple negative breast cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin</title>
            <description>Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2
+ Avastin 15 mg/kg
Q 3 weeks X 4 cycles
Bevacizumab/Avastin: IV 15mg/kg 21 days
Cyclophosphamide: 500mg per meter squared, IV every 21 days
Doxorubicin: 60 mg per meter squared, IV every 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pathologic Complete Response (pCR) Among Those With Triple Negative Breast Cancer</title>
          <description>pCR rate for triple negative patients--percent</description>
          <population>Patients with triple negative breast cancer</population>
          <units>% pCR among triple negative pts</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="35" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>If a subject experienced more than 1 of a given AE, the subject is only counted once for that AE. If a subject experienced more than one AE is a system organ class, the subject is only counted once in that system organ class.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin</title>
          <description>Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2
+ Avastin 15 mg/kg
Q 3 weeks X 4 cycles
Bevacizumab/Avastin: IV 15mg/kg 21 days
Cyclophosphamide: 500mg per meter squared, IV every 21 days
Doxorubicin: 60 mg per meter squared, IV every 21 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Issam Makhoul</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>5016868274</phone>
      <email>MakhoulIssam@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

